SciSparc Ltd. (Nasdaq: SPRC) has recently solidified its position in the pharmaceutical industry with the completion of the granting and validation process for its core-Technology patent in certain European countries. The patent covers combinations of cannabinoids and n-acylethanolamines, aligning seamlessly with the company’s proprietary technology designed to enhance the safety of cannabinoids while maintaining their therapeutic benefits.
This important milestone adds to SciSparc’s existing patent portfolio and supports the innovation of the company’s technologies. The patent was granted and validated in key European countries such as Austria, Belgium, France, Germany, and the United Kingdom, among others.
The invention at the core of this patent relates to compositions and methods for potentiating therapeutic effects and reducing side-effects of selected cannabinoids, originally discovered in the cannabis plant. The unique composition of cannabinoids and n-acylethanolamines, as well as the methods for their use in preventing and treating cannabinoid-related conditions, were key factors in the approval of this patent.
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company focused on developing therapies for disorders and rare diseases of the central nervous system. Led by an experienced team of senior executives and scientists, the company is actively engaged in drug development programs based on THC and/or non-psychoactive CBD for various conditions such as Tourette Syndrome, Alzheimer’s disease, pain, ASD, and status epilepticus.
In addition to its pharmaceutical endeavors, SciSparc also owns a controlling interest in a subsidiary that focuses on selling hemp seeds oil-based products on the Amazon.com Marketplace.
For more information, investors can contact SciSparc Ltd. at IR@scisparc.com or by calling +972-3-6167055.
For high-quality, engaging news and updates in the pharmaceutical industry, visit SciSparc Ltd.’s official website.
Read More Technology News
